The IgA Nephropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“IgA Nephropathy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the IgA Nephropathy Market.

Some of the key takeaways from the IgA Nephropathy Pipeline Report:

• Companies across the globe are diligently working toward developing novel IgA Nephropathy treatment therapies with a considerable amount of success over the years. 
• IgA Nephropathy companies working in the treatment market are Jiangsu HengRui Medicine Co., Ltd., Visterra, Chinook Therapeutics, Novartis Pharmaceuticals, Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, Ionis Pharmaceuticals, and others, are developing therapies for the IgA Nephropathy treatment 

• Emerging IgA Nephropathy therapies in the different phases of clinical trials are- HR19042, Sibeprenlimab, Atrasentan, LNP023, Sparsentan, Research programme-IgA proteases, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB LRx, and others are expected to have a significant impact on the IgA Nephropathy market in the coming years.   
• In December 2023, Novartis declared that the European Medicines Agency (EMA) awarded an orphan drug designation to iptacopan (LNP023) for IgA nephropathy (IgAN), as per the suggestion made by the Committee for Orphan Medicinal Products (COMP). Orphan drug designation is given to medications addressing life-threatening or chronically debilitating rare diseases, with a prevalence below 5 in 10,000 in the EU. These diseases either lack an approved method of diagnosis, prevention, or treatment, or the medication offers substantial benefits to individuals affected by the condition.
• In June 2023, Chinook Therapeutics, Inc. revealed a merger agreement with Novartis AG, wherein Novartis will purchase Chinook at $40 per share in cash, totaling $3.2 billion. This proposal presents an 83 percent premium over Chinook’s 60-day average stock price and a 67 percent premium over Chinook’s closing price on June 9, 2023.
• On November 2022, Ionis Pharmaceuticals, Inc. showcased encouraging findings from a Phase 2 clinical trial of IONIS-FB-LRx conducted among patients diagnosed with immunoglobulin A nephropathy (IgAN). The outcomes from this study were shared during a poster presentation at the American Society of Nephrology’s (ASN) Kidney Week 2022.
• On November 05, 2022, Vera Therapeutics, Inc. revealed recent clinical findings centered around the company’s two potential treatments: atacicept for immunoglobulin A nephropathy (IgAN) and MAU868 for kidney transplant. These findings were showcased through poster and oral presentations at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting, which took place from November 3 to November 6, 2022, in Orlando, Florida.

IgA Nephropathy Overview

IgA nephropathy, also known as Berger’s disease, stands as the predominant primary glomerular condition that may advance to end-stage renal failure (ESRD). The disease is characterized by a crucial interplay involving an inherent antigen (galactose-deficient IgA1) and antibodies against glycans in circulation, positioning IgA nephropathy within the spectrum of autoimmune disorders.

Get a Free Sample PDF Report to know more about IgA Nephropathy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight

Emerging IgA Nephropathy Drugs Under Different Phases of Clinical Development Include:

• HR19042: Jiangsu HengRui Medicine Co., Ltd.
• Sibeprenlimab: Visterra
• Atrasentan: Chinook Therapeutics
• LNP023: Novartis Pharmaceuticals
• Sparsentan: Travere Therapeutics
• Research programme: IgA proteases: Selecta Biosciences
• AP 305: Shanghai Alebund Pharmaceuticals
• ADR-001: Rohto Pharmaceutical
• MY 008: Wuhan Createrna Science and Technology
• SHR-2010: Guangdong Hengrui Pharmaceutical
• IONIS FB LRx: Ionis Pharmaceuticals

IgA Nephropathy Route of Administration

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

IgA Nephropathy Molecule Type

IgA Nephropathy Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

IgA Nephropathy Pipeline Therapeutics Assessment

• IgA Nephropathy Assessment by Product Type
• IgA Nephropathy By Stage and Product Type
• IgA Nephropathy Assessment by Route of Administration
• IgA Nephropathy By Stage and Route of Administration
• IgA Nephropathy Assessment by Molecule Type
• IgA Nephropathy by Stage and Molecule Type

DelveInsight’s IgA Nephropathy Report covers around 30+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further IgA Nephropathy product details are provided in the report. Download the IgA Nephropathy pipeline report to learn more about the emerging IgA Nephropathy therapies

Some of the key companies in the IgA Nephropathy Therapeutics Market include:

Key companies developing therapies for IgA Nephropathy are – Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others.

IgA Nephropathy Pipeline Analysis:

The IgA Nephropathy pipeline report provides insights into 

•  The report provides detailed insights about companies that are developing therapies for the treatment of IgA Nephropathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for IgA Nephropathy Treatment.
• IgA Nephropathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• IgA Nephropathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the IgA Nephropathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about IgA Nephropathy drugs and therapies

IgA Nephropathy Pipeline Market Drivers

• Increase in prevalence of IgA Nephropathy (IgAN), increment in the number of government initiatives to spread awareness are some of the important factors that are fueling the IgA Nephropathy Market.

IgA Nephropathy Pipeline Market Barriers

• However, lack of in-depth understanding of the disease pathogenesis, the unreported and undiagnosed IgA Nephropathy cases and other factors are creating obstacles in the IgA Nephropathy Market growth.

Scope of IgA Nephropathy Pipeline Drug Insight    

• Coverage: Global
• Key IgA Nephropathy Companies: Jiangsu HengRui Medicine Co., Ltd., Visterra, Chinook Therapeutics, Novartis Pharmaceuticals, Selecta Biosciences, Shanghai Alebund Pharmaceuticals, Rohto Pharmaceutical, Wuhan Createrna Science and Technology, Guangdong Hengrui Pharmaceutical, Ionis Pharmaceuticals, and others
• Key IgA Nephropathy Therapies: HR19042, Sibeprenlimab, Atrasentan, LNP023, Sparsentan, Research programme-IgA proteases, AP 305, ADR-001, MY 008, SHR-2010, IONIS FB LRx, and others
• IgA Nephropathy Therapeutic Assessment: IgA Nephropathy current marketed and IgA Nephropathy emerging therapies
• IgA Nephropathy Market Dynamics: IgA Nephropathy market drivers and IgA Nephropathy market barriers 

Request for Sample PDF Report for IgA Nephropathy Pipeline Assessment and clinical trials

Table of Contents

1. IgA Nephropathy Report Introduction

2. IgA Nephropathy Executive Summary

3. IgA Nephropathy Overview

4. IgA Nephropathy- Analytical Perspective In-depth Commercial Assessment

5. IgA Nephropathy Pipeline Therapeutics

6. IgA Nephropathy Late Stage Products (Phase II/III)

7. IgA Nephropathy Mid Stage Products (Phase II)

8. IgA Nephropathy Early Stage Products (Phase I)

9. IgA Nephropathy Preclinical Stage Products

10. IgA Nephropathy Therapeutics Assessment

11. IgA Nephropathy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. IgA Nephropathy Key Companies

14. IgA Nephropathy Key Products

15. IgA Nephropathy Unmet Needs

16 . IgA Nephropathy Market Drivers and Barriers

17. IgA Nephropathy Future Perspectives and Conclusion

18. IgA Nephropathy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/